Iksuda Therapeutics Ltd.
Clinical trials sponsored by Iksuda Therapeutics Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New HER2-Targeting drug shows promise in early cancer trial Results expected Dec 2026 (estimated)
- New Antibody-Drug shows promise for Hard-to-Treat lymphoma Results expected Sep 2027 (estimated)
-
New Antibody-Drug shows promise for Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. The drug works like a guided missile, targeting a protein (CD19) on cancer cells to deliver a toxic payload. The study aims to find…
Phase 1 • Sponsor: Iksuda Therapeutics Ltd. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New HER2-Targeting drug shows promise in early cancer trial
Disease control Recruiting nowThis study tests IKS014, a drug designed to seek out and destroy HER2-positive cancer cells, in people with advanced solid tumors like breast, stomach, and gastroesophageal cancers. The main goals are to find the safest dose and check for early signs of tumor shrinkage. About 165…
Phase 1 • Sponsor: Iksuda Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC